Once again this year, we can announce the results obtained on the reduction of our carbon footprint. From Moehs Group, we continue to strive and work hard to fulfil our commitment to respect the environment. MOEHS GROUP SPAIN has achieved a reduction of absolute CO2eq emissions in its SCOPE1+2 of more than 25%, being this […]

At Moehs Group, we collaborate every year with the Aula d’Extensió Universitària de Rubí, an organization dedicated to bringing knowledge and culture closer to adults in the city. We are proud to be part of this project and to contribute to making education accessible to everyone, regardless of age. Through this collaboration, we support a

We are pleased to share that a study developed by Moehs’ Research and Development team has been published in the scientific journal Biomedical Chromatography. This research focuses on nitroso-duloxetine impurity, a compound classified as a potentially genotoxic impurity, reinforcing our commitment to pharmaceutical safety and innovation.   Given the stringent requirements for controlling nitrosamines at

During 2024, our photovoltaic plants generated a total of 1,628,153 kWh of energy, contributing significantly to the reduction of our carbon footprint: MOEHS CATALANA S.L.: 506,309 Kwh MOEHS CANTABRA S.L.: 479.156 Kwh MOEHS BCN S.L.: 457.979 Kwh MOEHS IBERICA S.L.: 184.709 Kwh A very positive environmental impact with a maximum compensation of 814 tons of

At Moehs Group, we continue to advance our commitment to sustainability as a member of the Pharmaceutical Supply Chain Initiative (PSCI). One of our priorities is to address the Pharmaceuticals in the Environment (PIE) challenge, focused on understanding, controlling and reducing the presence of active ingredients in industrial waters, thus protecting rivers, lakes and seas.

Last 10th of December, our Site Manager, Josep Mª Casanovas, presented how we work at Moehs Group to continuously improve in the efficient use of water and the implementation of sustainable practices. The presentation took place during the XXII Jornada de Normas de Correcta Fabricación de Medicamentos y Principios Activos, in Barcelona, an important event

On 15th of November, Moehs Group team had the pleasure of collaborating in the Pharmaceutical Manufacturing Catskills 2024 training, organized at INS La Romànica, in Barberà del Vallès. A day full of learning for all participants, who worked on the manufacture of an ibuprofen suspension for children, demonstrating the talent and dedication of future professionals

Moehs Group, a leading international group in the production of active pharmaceutical ingredients, has signed an exclusive agreement with EUROAPI to take over the production of Metamizole, the active ingredient of Nolotil, at its facilities in Spain. This exclusive agreement between Moehs Group and EUROAPI aims to complete the evaluation of the technical transfer of

At Moehs Group we are very committed to caring for our planet and our activity strictly complies with each and every one of our commitments. With regard to our project to mitigate greenhouse gases, we have expanded the number of photovoltaic installations during the first semester of 2024. Between January and June 2024, the current

The Administration Board of the Centro para el Desarrollo Tecnológico y la Innovación, E.P.E (CDTI), has approved 2 important grants for Moehs Group: ABROCITINIB: development of a new chemical synthesis method of a janus kinase inhibitor active ingredient for the treatment of atopic dermatitis. VERICIGUAT: the objective is to develop a new method of chemical